Publications by authors named "Meneveau N"
Background: Although the benefit of supportive care in the postcancer period is now well demonstrated, its implementation in the patient journey remains challenging. This article describes the development, since 2015 and in routine care, of supportive postcancer care comprising a multidisciplinary rehabilitation programme (MRP) based on exercise for patients with early breast cancer.
Methods: As part of quality control, we reviewed all patient files since the programme was implemented.
Background: The optimal strategy in prosthetic heart valve thrombosis (PVT) remains controversial, with no randomized trials and conflicting observational data. We performed a systematic review and meta-analysis of evidence comparing systemic thrombolysis and cardiac surgery in PVT.
Methods And Results: We searched PubMed, the Cochrane Library, and Embase for studies on treatment strategies in patients with left-sided PVT since 2000.
Venous thromboembolism (VTE) is a common, serious condition that requires anticoagulation for at least three months to prevent recurrence and long-term complications. After this initial period, the decision to continue or stop anticoagulation depends on the balance between the risk of recurrent VTE and the risk of bleeding. Established guidelines suggest short-term anticoagulation for VTE caused by transient factors and indefinite anticoagulation for recurrent or cancer-associated VTE.
View Article and Find Full Text PDFArticle Synopsis
- Researchers started looking into using a special medicine called thrombolytic therapy to treat a serious condition called pulmonary embolism (PE) a few years after doctors first used a specific imaging test to diagnose it.
- In 1992, a doctor named Guy Meyer showed that using a medicine called alteplase helped patients with PE quickly feel better, but it also came with risks like serious bleeding.
- Now, ongoing studies like the PEITHO-3 trial are testing safer ways to use thrombolytics and other treatments for PE, focusing not just on saving lives, but also on how patients feel after recovery.
Context And Aims: Eribulin is used in taxane and anthracycline refractory HER2-negative metastatic breast cancers (MBC). Patients treated in pivotal clinical trials achieved low survival rates, therefore, the identification of prognostic criteria for long progression-free survival (PFS) is still an unmet medical need. In this study, we sought to determine potential prognostic criteria for long-term eribulin response in HER2-negative MBC.
View Article and Find Full Text PDFCancer is associated with increased muscle weakness, reduced physical functioning, increased fatigue, but also sleep disturbances, including insomnia, that affect quality of life (QoL). Physical activity demonstrated benefits on functional capacity, resilience and cancer-related fatigue, but there is a paucity of available data regarding its effects on insomnia in patients with cancer. This systematic review aims to examine the efficacy of exercise levels with insomnia in cancer patients.
View Article and Find Full Text PDFBackground And Aims: There is significant potential to streamline the clinical pathway for patients undergoing transcatheter aortic valve implantation (TAVI). The purpose of this study was to evaluate the effect of implementing BENCHMARK best practices on the efficiency and safety of TAVI in 28 sites in 7 European countries.
Methods: This was a study of patients with severe symptomatic aortic stenosis (AS) undergoing TAVI with balloon-expandable valves before and after implementation of BENCHMARK best practices.
High-risk pulmonary embolism (PE) refers to a large embolic burden causing right ventricular failure and hemodynamic instability. It accounts for approximately 5% of all cases of PE but contributes significantly to overall PE mortality. Systemic thrombolysis is the first-line revascularization therapy in high-risk PE.
View Article and Find Full Text PDFIntroduction: The PE-SARD score (syncope, anemia, renal dysfunction) was developed to predict the risk of major bleeding in the acute phase of pulmonary embolism (PE).
Methods: We analyzed data from 50,686 patients with acute PE included in the RIETE registry to externally validate the PE-SARD score. We calculated the overall reliability of the PE-SARD score, as well as discrimination and calibration for predicting the risk of major bleeding at 30 days.
Article Synopsis
- The KNOCOUT PE registry investigated the safety and efficacy of ultrasound-facilitated catheter-directed thrombolysis (USCDT) for treating acute pulmonary embolism (PE) in a diverse patient population across 64 sites worldwide.
- Among 489 patients treated with USCDT, the study found a low incidence of major bleeding (1.6%) and a low mortality rate (1.0%) within 30 days, while patients also reported improvements in their quality of life over 12 months.
- The findings support the use of USCDT with reduced doses of the thrombolytic agent alteplase (r-tPA), suggesting it can be done safely and effectively for patients at intermediate-high and high risk for
Background: Low fractional flow reserve (FFR) after percutaneous coronary intervention (PCI) has been associated with adverse clinical outcomes. Hitherto, this assessment has been independent of the epicardial vessel interrogated.
Objectives: This study sought to assess the predictive capacity of post-PCI FFR for target vessel failure (TVF) stratified by coronary artery.
Article Synopsis
- Clinical events can occur after percutaneous coronary intervention (PCI), especially in complex cases, and using advanced intracoronary imaging and pressure guidewires may help reduce these risks.
- The OPTI-XIENCE study is an international, multicenter prospective observational study involving 1,064 patients with specific high-risk characteristics undergoing stent implantation, monitoring them for 12 months.
- The study aims to evaluate the effectiveness of using these intracoronary tools, with the primary focus on the rate of target lesion failure after one year, while also assessing additional cardiovascular outcomes.
Article Synopsis
- The PFO-AF study aims to investigate the onset and recurrence of atrial fibrillation (AF) in patients who have undergone a procedure to close a patent foramen ovale (PFO) after suffering a stroke, utilizing implanted cardiac monitors for accurate data collection.
- It will involve 250 patients and track AF occurrences two months before and up to two years after the PFO closure, focusing on monitoring any AF episodes recorded by the cardiac device.
- The study is ethically approved and its results will be shared at conferences and in scientific journals to contribute to the understanding of AF in this patient population.
Background: Venous thromboembolism is a major complication of coronavirus disease 2019 (COVID-19). We hypothesized that a weight-adjusted intermediate dose of anticoagulation may decrease the risk of venous thromboembolism COVID-19 patients.
Methods: In this multicenter, randomised, open-label, phase 4, superiority trial with blinded adjudication of outcomes, we randomly assigned adult patients hospitalised in 20 French centers and presenting with acute respiratory SARS-CoV-2.
Background: The benefit related to the use of preprocedural computed tomography angiography (CCTA) on top of periprocedural echocardiography to plan percutaneous left atrial appendage closure (LAAC) procedures is still unclear.
Objectives: The authors sought to evaluate the impact of preprocedural CCTA on LAAC procedural success.
Methods: In the investigator-initiated SWISS-APERO (Comparison of Amplatzer Amulet and Watchman Device in Patients Undergoing Left Atrial Appendage Closure) trial, patients undergoing echocardiography-guided LAAC were randomly assigned to receive the Amulet (Abbott) or Watchman 2.
Introduction: We prospectively investigated whether home treatment of pulmonary embolism (PE), is as effective and safe as the recommended early discharge management in terms of outcomes at 3 months.
Methods: We performed a post hoc analysis of prospectively and consecutively recorded data in acute PE patients from a tertiary care facility between January 2012 and November 2021. Home treatment was defined as discharge to home directly from the emergency department (ED) after <24 h stay.
Background: Up to 70% of breast cancer patients report symptoms of insomnia during and after treatment. Despite the ubiquity of insomnia symptoms, they are under-screened, under-diagnosed and poorly managed in breast cancer patients. Sleep medications treat symptoms but are ineffective to cure insomnia.
View Article and Find Full Text PDFObjective: To determine the prognostic impact of coronary artery disease (CAD) in patients randomized to bivalirudin or unfractionated heparin (UFH) during transcatheter aortic valve replacement (TAVR).
Background: CAD is a common comorbidity among patients undergoing TAVR and studies provide conflicting data on its prognostic impact.
Methods: The Bivalirudin on Aortic Valve Intervention Outcomes-3 (BRAVO-3) randomized trial compared the use of bivalirudin versus UFH in 802 high-surgical risk patients undergoing transfemoral TAVR for severe symptomatic aortic stenosis.
Background: Transcatheter aortic valve implantation now has a major role in the treatment of patients with severe aortic stenosis. However, evidence is scarce on its feasibility and safety to treat patients with pure aortic regurgitation.
Aims: We sought to evaluate the results of transcatheter aortic valve implantation using the balloon-expandable SAPIEN 3 transcatheter heart valve (Edwards Lifesciences, Irvine, CA, USA) in patients with pure aortic regurgitation on native non-calcified valves.
Background: Right ventricular (RV) function plays a critical role in the pathophysiology and acute prognosis of pulmonary embolism (PE). We analyzed the temporal changes of RV function in the cohort of a prospective multicentre study investigating if an early switch to oral anticoagulation in patients with intermediate-risk PE is effective and safe.
Methods: Echocardiographic and laboratory examinations were performed at baseline (PE diagnosis), 6 days and 6 months.
Background: Trastuzumab is used, alone or in conjunction with standard chemotherapy, to treat HER2-positive breast cancer (BC). Although it improves cancer outcomes, trastuzumab. can lead to cardiotoxicity.
View Article and Find Full Text PDFThere is a growing clinical and scientific interest in catheter-directed therapy (CDT) of acute pulmonary embolism (PE). Currently, CDT should be considered for patients with high-risk PE, in whom thrombolysis is contraindicated or has failed. Also, CDT is a treatment option for initially stable patients in whom anticoagulant treatment fails, i.
View Article and Find Full Text PDF